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the same did equally well in the clinical trials
strongly suggests that there are other causes
for the poorer outcomes and mortality rates
experienced by Black men with mCRPC.”
This study was one of a series that Dr. Kelly and
his colleagues are conducting on treatments
and other factors that may underpin disparities.
“Our ultimate goal is to help pinpoint the drivers
of prostate cancer disparities—in particular,
whether they are biologically based or result from
differences in factors such as quality of care, access
to care, or social determinates of health—and
identify ways to eliminate them,” Dr. Kelly says.

Striving to Understand
Disparities in Cancer Care
A key element of the mission of the Sidney
Kimmel Cancer Center–Jefferson Health—and
an objective of many researchers across the
University—is to understand and mitigate the
disparities in cancer incidence, treatment and
outcome too often experienced by patients
who are African American or Latinx, have low
incomes or have limited access to care.
In the Philadelphia region, for example, prostate
cancer incidence and mortality rates are significantly
higher for African Americans than Caucasians, but
the causes of this major disparity are unknown.
Many researchers have believed that the difference
in outcomes results from African American men’s
poor clinical response to existing treatment for
advanced disease, as compared to Caucasian men’s
response. But a groundbreaking study—led by William
Kevin Kelly, DO, professor of medical oncology and
urology—directly challenges that long-held concept.
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“Indeed, the study is paradigm shifting,” observes
Karen E. Knudsen, MBA, PhD, CEO of the American
Cancer Society, former enterprise director of the
NCI-designated Sidney Kimmel Cancer Center.
Dr. Kelly’s study was a meta-analysis of patient
data from 8,820 men with metastatic castrationresistant prostate cancer (mCRPC) who had been
treated with a docetaxel and prednisone (DP)-based
regimen during nine phase III clinical trials. The
group included men who self-identified as either
Caucasian, Black or Asian (with four percent not
specifying). The primary goal of the analysis was to
compare the response to therapy and overall survival.
The results: “We observed no differences in
clinical outcomes by race and ethnic groups,”
says Dr. Kelly. “And, in this case, ‘no difference’ is
a highly significant finding. The fact that Black,
Asian and Caucasian men who were treated

Although the use of a relatively new, effective and
less-expensive breast cancer treatment is on the
rise, African American women and those without
private insurance are too frequently not offered
the therapy. As part of a comprehensive treatment
plan, the approach—called hypofractionated
whole breast radiation (HR)—delivers a higher
radiation dose per treatment than the traditional
regimen, and cuts the number of treatment
sessions roughly in half. The HR approach is as
effective as the traditional approach at reducing
the risk of the cancer returning for most women.
It is also more cost-effective and offers many
patients fewer side effects and better breast
restoration outcomes following treatment.
Unfortunately, in a study of nearly 260,000 earlystage breast cancer patients, Alliric Willis, MD,
MSPH, professor of surgery and vice chair and
assistant dean for faculty affairs, and research
colleagues found that patients who identified as
Caucasian were most likely to receive HR, while
those who identified as African American were least
likely. “Taking all other factors into account, African
American women were 15 percent less likely to be
treated with HR than Caucasian women,” he says.
“Thus, even though treatment guidelines do not take
race into account, it is clearly a factor in delivery
of this often-preferred breast cancer treatment.”
Socioeconomic status also apparently affects
the delivery of HR therapy: patients with private
insurance were more likely to receive HR than were
uninsured patients or those on Medicaid; and those
who lived in the highest-income zip codes were
much more likely to undergo HR than patients
from lowest-income zip codes. As well, treatment
facilities associated with academic medical centers
were twice as likely to use HR as community
cancer or integrated network cancer facilities.
“Patients should have access to all treatment
options no matter their race, socioeconomic
background or where they seek care,” Dr. Willis

says. “We hope that our research will help to
address gaps in provider education and extend
this favorable treatment to all patients.”
Lung cancer treatment is another area where racial
disparities persist—in both outcomes and treatment
types. For example, although African American
patients are now more likely than they were a
decade ago to receive the most-effective treatment
for early-stage non-small cell lung cancer, they
continue to be less likely than Caucasian patients to

We must keep working to reduce
barriers to successful treatments for
Black patients across cancer types,
and better understanding drivers of
these inequities is key to fixing them.”
Olugbenga Okusanya, MD

receive that treatment. Surgical removal of a portion
of lung is the most-effective current treatment; and
two types of radiation therapy are used as a secondline therapy, with stereotactic ablative radiotherapy
shown to be more effective than external beam
radiation therapy for early-stage disease.
Assistant professor of surgery Olugbenga
Okusanya, MD, and research colleagues examined
information on 192,415 patients in the National
Cancer Database to try to understand whether
reliance on second-line treatments for African
American patients has contributed to the disparities
in long-term outcomes across populations.
“We found some progress being made in closing
the disparity in the utilization of surgery in Black
patients,” says Dr. Okusanya, “and no disparity across
racial groups in use of the two second-line therapies.
Additionally, while other studies have suggested that
comorbidities in Black patients were one of the drivers
for worse outcomes—rather than the lower utilization
of surgery—our research found that when Black
patients get surgery there is actually a trend for them
to have better survival than their white counterparts.”
Dr. Okusanya’s studies on disparities in cancer care
continue. “We must keep working to reduce barriers
to successful treatments for Black patients across
cancer types,” he says, “and better understanding
drivers of these inequities is key to fixing them.” 
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